Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05209100 · ClinicalTrials.gov registry record
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
A clinical trial of Non-alcoholic Fatty Liver Disease, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT05209100 is a study of Non-alcoholic Fatty Liver Disease that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 38 participants, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05209100, a study of Non-alcoholic Fatty Liver Disease, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease. In parallel, the investigators will establish a biobank that will allow future studies to reveal how encroachment is connected to host metabolism and liver physiology, including the composition and function of the fecal microbiome.
Conditions Studied
Interventions
- PROCEDURE Sigmoidoscopy
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05209100
The ClinicalTrials.gov registry entry for NCT05209100 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (80% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Sigmoidoscopy is the first listed.
NCT05209100 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05209100 about?
NCT05209100 is a clinical study titled "Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease". This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease. In parallel, the investigators will establish a biobank that will allow future studies to reveal how encroachment is connected to host metabolism and liver physiology,...
What is the current status of trial NCT05209100?
This trial is currently active not recruiting. The enrollment target is 38 participants. The study started on 2022-02-11. Estimated completion is 2025-12.
What conditions does trial NCT05209100 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT05209100?
The interventions under investigation include: Sigmoidoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT05209100?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05209100 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.